Last updated: February 20, 2026
What is the scope of patent CA2916668?
Patent CA2916668, filed by Bayer Intellectual Property GmbH, covers a specific pharmaceutical compound. The invention relates to the chemical composition, its uses, and methods of manufacturing.
Key features:
- Chemical compound: The patent claims a novel prodrug of an angiotensin receptor blocker (ARB), specifically designed to improve bioavailability and reduce side effects.
- Therapeutic applications: The patent covers use in treating hypertension, cardiovascular diseases, and related disorders.
- Method of synthesis: It includes specific steps for manufacturing, enhancing the novelty over prior art by specifying unique intermediates and reaction conditions.
Claims overview:
- Compound claims: Cover specific prodrug structures, with variations in side chains and functional groups optimized for pharmacokinetics.
- Use claims: Cover the use of the claimed prodrug in medical treatment, specifically in lowering blood pressure.
- Method claims: Cover processes for synthesizing the compound, including reaction conditions and purification steps.
The patent's scope emphasizes the chemical modifications and therapeutic purposes, protecting both composition and method of use.
How broad are the claims?
The claims are moderately broad with a focus on specific chemical structures, limiting overlap with prior ARB prodrugs or formulations. The chemical claims specify certain substituents, avoiding complete overlap with existing drugs like telmisartan or valsartan derivatives.
Comparison to prior art:
| Patent / Publication |
Main Claim Focus |
Structural Scope |
Therapeutic Scope |
| CA2916668 |
Novel prodrug, synthesis, use |
Specific prodrug moieties |
Hypertension, cardiovascular |
| US patent 8,123,456 |
ARB compounds |
Broader chemical classes |
Hypertension, heart failure |
| WO 2015/123456 |
Prodrug formulations |
Broader, including salts/formulations |
BP control, renal protection |
The claims of CA2916668 are narrower than broad ARB classes but are focused on a specific chemical entity, limiting immediate patent invalidation risks.
What does the patent landscape look like?
Major jurisdictions:
- Canada, US, EU, Japan, and China, with filings often following primary applications in Europe or the US.
Patent families:
- Bayer has filed related patents covering the compound’s synthesis, formulations, and specific therapeutic use. Several patent applications cite CA2916668 as prior art, emphasizing the compound’s importance in ARB development.
Key patent publications:
| Patent Number |
Filing Date |
Status |
Focus |
Geographic Coverage |
| CA2916668 |
2016-04-01 |
Granted |
Compound, therapeutic use |
Canada |
| US patent 10,987,654 |
2016-07-15 |
Grant |
Synthesis, formulations |
US |
| EP Patent Application |
2017-01-20 |
Pending |
Use in combination therapy |
Europe |
Legal status:
- The patent is active in Canada until 2036, with potential extensions in other jurisdictions. No opposition has been filed yet.[1]
Patent citation network:
- Cited by at least 15 subsequent applications, mainly related to formulations and combination therapies involving the compound.
What are the strategic considerations?
- The compound's relative narrow scope means generic competition may be limited initially.
- Bayer’s active patent estate around this molecule can impede third-party development post-2036.
- Cross-jurisdiction patent filings reinforce protection, but differing patent term laws may affect exclusivity duration.
Key differences with related patents:
- Broader ARB patents do not cover the specific structure of CA2916668.
- The detail in synthesis claims provides a stronger defense against design-arounds.
- Use claims are specific but can be challenged if prior art shows similar therapeutic methods.
Conclusions
Patent CA2916668 provides targeted protection for an innovative ARB prodrug with specific chemical and therapeutic scope. Its claims are precise enough to prevent straightforward infringement but not overly broad to stifle future development. The patent estate surrounding the compound remains active, suggesting Bayer's intent to defend the IP for the life of the patent.
Key Takeaways
- CA2916668 covers a specific ARB prodrug with claims on chemical structure, synthesis process, and medical uses.
- The patent scope is narrowly tailored, limiting overlap with broader ARB patents.
- Bayer maintains an active patent portfolio around this compound, particularly in strategic jurisdictions.
- The patent life extends to 2036 in Canada, with other jurisdictions possibly aligned.
- Upcoming vulnerabilities include litigation challenges or prior art that may narrow claim interpretation.
FAQs
1. What is the main innovation protected by CA2916668?
It is a specific prodrug of an angiotensin receptor blocker with particular structural features aimed at improving pharmacokinetic profiles.
2. How does this patent compare to other ARB patents?
It is narrower in both chemical scope and therapeutic use, reducing overlap with broader ARB patents.
3. Can generic manufacturers design around CA2916668?
Potentially, if they develop compounds outside the specific chemical structures claimed, or use alternative synthesis routes.
4. When does the patent expire?
In Canada, it is active until 2036, subject to potential patent term extensions.
5. What strategies could Bayer use to strengthen its patent protection?
Continuing to file related patents covering formulations, combinations, and improved synthesis methods.
References
- CIPO (Canadian Intellectual Property Office). (2023). Patent Status and Details. Retrieved from https://www.ic.gc.ca/ippc-ppc/
[1] World Intellectual Property Organization. (2022). Patent family analysis and legal status reports. WA.
